Breast Cancer, Criscitiello (Aiom): "Genomic Test Helps Define Ideal Therapy"
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.8 Articles
8 Articles
If patients are diagnosed in a grey zone, where the traditional histologic examination does not fully clarify the usefulness of the therapy, the genomic test is a valid tool for making a more informed and informed decision. In this way it is possible to administer chemotherapy only to women who would benefit from it, saving it to those who would have only side effects and a negative impact on the quality of daily life.
(Adnkronos) "The result of the genomic test," evaluated within a broader context that includes parameters such as the size of the tumor, the possible involvement of the axillary lymph nodes, the expression of hormonal receptors, the proliferative index and the degree of neoplasm, helps us define the ideal treatment. Therefore, for those patients who are [...]
canaledieci.it
The result of the genomic test, which is assessed within a broader context that includes parameters such as the size of the tumor, the possible involvement of the axillary lymph nodes, the expression of hormonal receptors, the proliferative index and the degree of neoplasm, helps us define the ideal treatment. Consequently, for those patients who are diagnosed with [...]
notizie.it
Rec News | Lontani dal mainstream(Adnkronos) - "The result of the genomic test," evaluated within a broader context that includes parameters such as the size of the tumor,
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
